Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Incyte to Report Third Quarter Financial Results
08:00am, Tuesday, 08'th Oct 2024
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 29, 2
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11:08pm, Monday, 07'th Oct 2024
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Thursday, 03'rd Oct 2024
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
03:01pm, Wednesday, 25'th Sep 2024
Though INCY's performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise investors to wait and watch before turning positive.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Multiple Late-Breaking Data Presentations from Incyte's Dermatology Portfolio will be Featured at the EADV 2024 Congress.
– Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg every 2 weeks dose achieving a complete or partial response within the first six months of treatment �
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
02:44pm, Wednesday, 18'th Sep 2024
Truist Securities has downgraded Incyte Corporation INCY, noting Jakafi's (ruxolitinib) patent loss approaching in 2028.
Incyte Announces Promising New Data on Oncology Candidate at ESMO
02:26pm, Monday, 16'th Sep 2024
INCY's INCB123667 data show the candidate's potential as a differentiated treatment option for cancers with increased cyclin E1 activity, amplification and/or overexpression in cells predictive of CDK
Doğuş Technology and Doğuş Construction Participate in ConteQ Expo 2024 with Innovative Projects
01:30am, Sunday, 15'th Sep 2024
DOHA, Qatar--(BUSINESS WIRE)--Doğuş Technology, one of Turkey's leading tech companies, will showcase its innovative, technology-driven solutions for the construction industry at ConteQ Expo 2024, a
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte's CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer.
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Monday, 09'th Sep 2024
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Incyte (INCY) Up 0.9% Since Last Earnings Report: Can It Continue?
12:37pm, Thursday, 29'th Aug 2024
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data
03:04pm, Monday, 19'th Aug 2024
Incyte Corporation reported positive results achieved from Phase 3 study using Monjuvi for the treatment of patients with relapsed/refractory follicular lymphoma. Supplemental Biologics License Applic
Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug
02:20am, Saturday, 17'th Aug 2024
Incyte???s (INCY) late-stage study on tafasitamab for patients with relapsed or refractory follicular lymphoma meets its goal. FDA approves axatilimab for the treatment of chronic graft-versus-host di
Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study
09:29am, Friday, 16'th Aug 2024
On Friday, Incyte Corporation INCY released topline results from the pivotal Phase 3 inMIND trial evaluating the efficacy and safety of Monjuvi (tafasitamab) and lenalidomide as an add-on to rituxima
